Literature DB >> 22033913

[Systemic amyloidoses].

S Schönland1, N Blank, A V Kristen, J Beimler, T Ganten, U Hegenbart.   

Abstract

Amyloidoses are rare protein folding disorders, in which proteins are deposited as insoluble fibrillar aggregates due to a conformational change. This can occur in a local or systemic form. Systemic amyloidoses are life-threatening complications of monoclonal gammopathy, chronic inflammatory diseases or within hereditary diseases. The causative treatment of amyloidosis is the reduction of the amyloid precursor protein by chemotherapy, anti-inflammatory treatment, or liver transplantation. Early diagnosis of the disease is essential in order to effectively treat patients and avoid further deterioration of organ functions.

Entities:  

Mesh:

Year:  2012        PMID: 22033913     DOI: 10.1007/s00108-011-2952-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  17 in total

1.  Suspected cardiac amyloidosis: endomyocardial biopsy remains the diagnostic gold-standard.

Authors:  Arnt V Kristen; Thomas J Dengler; Hugo A Katus
Journal:  Am J Hematol       Date:  2007-04       Impact factor: 10.047

2.  Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.

Authors:  L M Dember; V Sanchorawala; D C Seldin; D G Wright; M LaValley; J L Berk; R H Falk; M Skinner
Journal:  Ann Intern Med       Date:  2001-05-01       Impact factor: 25.391

Review 3.  Amyloidosis: is a cure possible?

Authors:  G Merlini; G Palladini
Journal:  Ann Oncol       Date:  2008-06       Impact factor: 32.976

4.  99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy.

Authors:  Max Puille; Klaus Altland; Reinhold P Linke; Mary K Steen-Müller; Rigobert Kiett; Dagmar Steiner; Richard Bauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03       Impact factor: 9.236

5.  High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Authors:  Martha Skinner; Vaishali Sanchorawala; David C Seldin; Laura M Dember; Rodney H Falk; John L Berk; Jennifer J Anderson; Carl O'Hara; Kathleen T Finn; Caryn A Libbey; Janice Wiesman; Karen Quillen; Niall Swan; Daniel G Wright
Journal:  Ann Intern Med       Date:  2004-01-20       Impact factor: 25.391

6.  Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry.

Authors:  Gustaf Herlenius; Henryk E Wilczek; Marie Larsson; Bo-Göran Ericzon
Journal:  Transplantation       Date:  2004-01-15       Impact factor: 4.939

7.  Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.

Authors:  Helen J Lachmann; David R Booth; Susanne E Booth; Alison Bybee; Janet A Gilbertson; Julian D Gillmore; Mark B Pepys; Philip N Hawkins
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

Review 8.  The molecular biology and clinical features of amyloid neuropathy.

Authors:  Merrill D Benson; John C Kincaid
Journal:  Muscle Nerve       Date:  2007-10       Impact factor: 3.217

Review 9.  Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.

Authors:  Maria João Mascarenhas Saraiva
Journal:  Expert Rev Mol Med       Date:  2002-05-14       Impact factor: 5.600

10.  Natural history and outcome in systemic AA amyloidosis.

Authors:  Helen J Lachmann; Hugh J B Goodman; Janet A Gilbertson; J Ruth Gallimore; Caroline A Sabin; Julian D Gillmore; Philip N Hawkins
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more
  2 in total

1.  [A 48-year-old patient with oligoarthritis of the knees, having excluded spondyloarthritis and rheumathoid arthritis].

Authors:  M Gehlen; S Janik; P Dudko; M Schwarz-Eywill
Journal:  Internist (Berl)       Date:  2014-04       Impact factor: 0.743

Review 2.  [Inherited heart diseases and storage diseases with cardiac involvement].

Authors:  Frauke S Czepluch; Gerd Hasenfuß
Journal:  Internist (Berl)       Date:  2018-10       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.